Home / News / India News / Article / 'Seropositivity rate, anti-spike antibody higher in Covishield than Covaxin'

'Seropositivity rate, anti-spike antibody higher in Covishield than Covaxin'

The results found that among the 515 HCW (305 Male, 210 Female), 95.0 per cent showed seropositivity after two doses of both vaccines.

Listen to this article :
Photo used for representational purpose. Pic/AFP

Photo used for representational purpose. Pic/AFP

A latest study has found that both vaccines, Covishield and Covaxin elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.

The study is titled, Antibody Response after Second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study published in MedRxiv.

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All

Advertisement